Intellia Therapeutics

(NASDAQ) NTLA

Current Price$14.12

Market Cap$1.66B

Since IPO (2016)-36%

5 Year-79%

1 Year+70%

1 Month+2%

Intellia Therapeutics Financials at a Glance

Market Cap

$1.66B

Revenue (TTM)

$67.67M

Net Income (TTM)

$412.69M

EPS (TTM)

$-3.83

P/E Ratio

-3.68

Dividend

$0.00

Beta (Volatility)

1.95 (High)

Dividend

$0.00

Beta (Volatility)

1.95 (High)

Price

$14.12

Volume

194,233

Open

$14.02

Price

$14.12

Volume

194,233

Open

$14.02

Previous Close

$14.12

Daily Range

$13.74 - $14.54

52-Week Range

$6.83 - $28.25

Dividend

$0.00

Beta (Volatility)

1.95 (High)

Price

$14.12

Volume

194,233

Open

$14.02

Previous Close

$14.12

Daily Range

$13.74 - $14.54

52-Week Range

$6.83 - $28.25

NTLA News

Page 1

NTLA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Intellia Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

377

CEO

John M. Leonard, MD

Website

www.intelliatx.com

Headquarters

Cambridge, MA 02139, US

NTLA Financials

Key Financial Metrics (TTM)

Gross Margin

-26%

Operating Margin

-7%

Net Income Margin

-6%

Return on Equity

-53%

Return on Capital

-60%

Return on Assets

-49%

Earnings Yield

-27.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.66B

Shares Outstanding

118.13M

Volume

194.23K

Avg. Volume

4.89M

Financials (TTM)

Gross Profit

$51.75M

Operating Income

$440.99M

EBITDA

$396.77M

Operating Cash Flow

$348.88M

Capital Expenditure

$5.78M

Free Cash Flow

$354.66M

Cash & ST Invst.

$449.88M

Total Debt

$93.33M

Intellia Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$23.02M

+78.8%

Gross Profit

$17.00M

+32.1%

Gross Margin

73.87%

N/A

Market Cap

$1.66B

N/A

Market Cap/Employee

$4.13M

N/A

Employees

403

N/A

Net Income

$95.79M

+25.7%

EBITDA

$95.41M

+28.7%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$356.56M

-8.9%

Accounts Receivable

$9.47M

+11.2%

Inventory

$0.00

N/A

Long Term Debt

$66.85M

-64.8%

Short Term Debt

$26.48M

+30.8%

Return on Assets

-49.01%

N/A

Return on Invested Capital

-59.74%

N/A

Free Cash Flow

$69.41M

+19.5%

Operating Cash Flow

$69.28M

+18.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ZYMEZymeworks Inc.

ZYMEZymeworks Inc.$23.89-10.19%

BCRXBioCryst Pharmaceuticals, Inc.

BCRXBioCryst Pharmaceuticals, Inc.$8.62-3.15%

WVEWave Life Sciences Ltd.

WVEWave Life Sciences Ltd.$7.18-0.83%

PHVSPharvaris N.V.

PHVSPharvaris N.V.$30.09+1.38%

IMNMImmunome, Inc.

IMNMImmunome, Inc.$22.44+1.13%

STOKStoke Therapeutics, Inc.

STOKStoke Therapeutics, Inc.$32.89+0.30%

BHVNBiohaven Ltd.

BHVNBiohaven Ltd.$9.86+1.28%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

RXTRackspace Technology

RXTRackspace Technology$5.49+0.56%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.62+0.08%

NOKNokia

NOKNokia$12.82+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.28+0.07%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.57-0.07%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.35+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$15.75-0.02%

Questions About NTLA

What is the current price of Intellia Therapeutics?

Intellia Therapeutics is trading at $14.12 per share.

What is the 52-week range for Intellia Therapeutics?

Over the past 52 weeks, Intellia Therapeutics has traded between $6.83 and $28.25.

How much debt does Intellia Therapeutics have?

As of the most recent reporting period, Intellia Therapeutics reported total debt of $93.33M.

How much cash does Intellia Therapeutics have on hand?

Intellia Therapeutics reported $155.46M in cash and cash equivalents in its most recent financial results.

What is Intellia Therapeutics’s dividend yield?

Intellia Therapeutics does not currently have a dividend yield.

Intellia Therapeutics

Intellia Therapeutics Financials at a Glance

NTLA News

Best Gene Editing Stocks for 2026 and How to Invest

Best CRISPR Companies to Buy in 2026 and How to Invest in Them

This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?

Top ETFs Tracking CRISPR Gene Editing for 2026

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?

Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street

2 Beaten-Down Stocks to Avoid Right Now

NTLA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Intellia Therapeutics

NTLA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Intellia Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NTLA

What is the current price of Intellia Therapeutics?

What is the 52-week range for Intellia Therapeutics?

How much debt does Intellia Therapeutics have?

How much cash does Intellia Therapeutics have on hand?

What is Intellia Therapeutics’s dividend yield?

Premium Investing Services